
-
Akari Therapeutics NasdaqCM:AKTX Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) and a novel discovery engine. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. In addition, its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. Further, the company develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
Location: 22 Boston Wharf Road, Boston, MA, 02210, United States | Website: https://www.akaritx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
73.69B
Cash
2.582M
Avg Qtr Burn
-2.665M
Short % of Float
-
Insider Ownership
34.40%
Institutional Own.
0.98%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Nomacopan Details Paroxysmal nocturnal hemoglobinuria | Phase 3 Update | |
Nomacopan Details Hematopoietic stem cell transplantation thrombotic microangiopathies | Phase 3 Initiation | |
Nomacopan Details COVID-19 | Phase 2 Update | |
Nomacopan Details Atopic Keratoconjunctivitis | Phase 1/2 Update | |
Nomacopan Details Geographic atrophy, Eye disease | Phase 1 Initiation | |
Nomacopan Details Bullous pemphigoid | Failed Discontinued |